Breckenridge and Aptalis announced the launch of Propranolol HCl Extended-Release Capsules, the generic version of Akrimax’s Inderal LA. Inderal LA is a non-selective beta-blocker indicated for the treatment of hypertension, angina pectoris due to coronary atherosclerosis, migraine, and hypertrophic subaortic stenosis.
Propranolol HCl blocks beta-receptor sites to decrease the chronotropic, inotropic, and vasodilator responses. Propranolol HCl also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential.
Under the agreement, Aptalis will manufacture and supply the product to Breckenridge, who will have exclusive marketing and distribution rights. Propranolol HCl Extended-Release Capsules are available in 60mg, 80mg, 120mg, and 160mg strengths. The companies have already begun shipping the product.
For more information call (561) 443-3314 or visit www.bpirx.com.